Andrade Luis Jesuíno de Oliveira, Atta Ajax Mercês, D'Almeida Junior Argemiro, Paraná Raymundo
Post-Graduate Course in Medicine and Health, Medicine School, Federal University of Bahia, Salvador, BA, Brazil.
Braz J Infect Dis. 2008 Apr;12(2):144-8. doi: 10.1590/s1413-86702008000200009.
Hepatitis C (HCV) is now the main cause of chronic hepatic disease, cirrhosis and hepatocellular carcinoma. Several extrahepatic diseases have been associated with chronic HCV infection, and in most cases appear to be directly related to the viral infection. Thyroid disorders are common in patients with chronic HCV. Some patients with chronic hepatitis C experience thyroid problems, and thyroid dysfunction may also be a side effect of interferon-based treatment. The principal risk factor for developing thyroid disease in the course of antiviral therapy is the previous positivity for anti-thyroid antibodies (anti-thyroid peroxidase) especially in older women. Screening for autoantibodies and serum thyroid-stimulating hormone is recommended before, during and after interferon-alpha treatment, and patients should be informed of the risk of thyroid dysfunction. This review includes a summary of thyroid disease associated with chronic HCV infection, interferon-alpha and ribavirin for treatment of HCV and potential to induce thyroid dysfunction.
丙型肝炎(HCV)现已成为慢性肝病、肝硬化和肝细胞癌的主要病因。几种肝外疾病与慢性HCV感染有关,且在大多数情况下似乎与病毒感染直接相关。甲状腺疾病在慢性HCV患者中很常见。一些慢性丙型肝炎患者会出现甲状腺问题,甲状腺功能障碍也可能是基于干扰素治疗的副作用。抗病毒治疗过程中发生甲状腺疾病的主要危险因素是既往抗甲状腺抗体(抗甲状腺过氧化物酶)呈阳性,尤其是老年女性。建议在使用α干扰素治疗前、治疗期间和治疗后筛查自身抗体和血清促甲状腺激素,并且应告知患者甲状腺功能障碍的风险。这篇综述总结了与慢性HCV感染、用于治疗HCV的α干扰素和利巴韦林相关的甲状腺疾病以及诱导甲状腺功能障碍的可能性。